English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/123906
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Improved drugability of vasoactive intestinal peptide (VIP) by nanotechnology for therapeutic selective targeting and immunomodulation

AuthorsPozo, David ; López-Enriquez, Soledad; Klippstein, Rebecca
Issue Date4-Nov-2012
CitationXI International Congress of Neuroimmunology (2012)
AbstractNanotechnology can address key bottlenecks hindering successful bench to bedside translation of recent research in the development of neuropeptide-based drugs. This is the case for vasoactive intestinal peptide (VIP), where sustained interest in its therapeutic applications needs to devise new methodologies to improve its drugability or to convey innovation to diagnostics to identify cells that result from conditions such as carcinoid metastasis in which VPAC receptors are involved. Here we present our results covering the chemical synthesis and functional characterisation of VIP Au/Ag nanoparticles, the protective effects on protease-based degradation, and the specific target to tumor cells or dendritic cells as an approach to cell therapy by using VIP-nanoliposomes.
DescriptionPóster presentado en el XI International Congress of Neuroimmunology (ISNI), celebrado en Boston (USA) del 4 al 8 de noviembre de 2012
URIhttp://hdl.handle.net/10261/123906
Appears in Collections:(CABIMER) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.